Cardiac stem cell trials and the new world of cellular reprogramming: Time to move on
- 1 April 2018
- journal article
- editorial
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 155 (4) , 1642-1646
Abstract
No abstract availableKeywords
Funding Information
- National Heart Lung and Blood Institute (R01 HL121294-01A1)
This publication has 24 references indexed in Scilit:
- Induced Pluripotent Stem Cells for Post–Myocardial Infarction RepairCirculation Research, 2014
- Implantation of CD133+ Stem Cells in Patients Undergoing Coronary Bypass Surgery: IMPACT-CABG Pilot TrialCanadian Journal of Cardiology, 2013
- In Vivo Cardiac Cellular Reprogramming Efficacy Is Enhanced by Angiogenic Preconditioning of the Infarcted Myocardium With Vascular Endothelial Growth FactorJournal of the American Heart Association, 2012
- Heart repair by reprogramming non-myocytes with cardiac transcription factorsNature, 2012
- Cardiac Biointerventions Whatever Happened to Stem Cell and Gene Therapy?Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2012
- In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytesNature, 2012
- Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formationAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Stem-cell therapy for cardiac diseaseNature, 2008
- Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined FactorsCell, 2006
- Inhibition of the Cardiac Angiogenic Response to Surgical FGF-2 Therapy in a Swine Endothelial Dysfunction ModelCirculation, 2003